TLDR
- IBRX jumps 11.6% after EMA backs ANKTIVA for bladder cancer treatment.
- EMA nod boosts IBRX as price breaks above $2.30 with bullish strength.
- ANKTIVA earns EU support, sending ImmunityBio (IBRX) shares soaring
- IBRX rallies near $2.50 after EMA recommendation fuels ANKTIVA hopes.
- ImmunityBio gains EU traction, lifting IBRX stock on strong momentum.
IBRX stock surged sharply, rising approximately 11.6% intraday following the European Medicines Agency’s positive opinion on ANKTIVA. The price broke above the $2.30 range and hovered near $2.45, indicating strong market reaction and momentum. With this decisive move, IBRX caught attention as it approached the $2.50 short-term resistance level.
EMA Endorses Conditional Authorization for ANKTIVA in Europe
The European Medicines Agency (EMA) issued a positive recommendation for conditional marketing authorization of ANKTIVA in the European Union. ANKTIVA, combined with Bacillus Calmette-Guérin (BCG), targets BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. This endorsement marks a key regulatory milestone for IBRX in expanding global access to its lead immunotherapy.
The EMA recognized ANKTIVA’s potential to address unmet needs where bladder removal remains the only remaining treatment option. IBRX aims to offer a non-surgical solution, especially valuable for NMIBC patients ineligible or unwilling to undergo radical cystectomy. The company expects final approval from the European Commission following this scientific endorsement.
The decision was based on trial results showing a 71% complete response rate in patients treated with ANKTIVA and BCG. IBRX will submit ongoing post-marketing data to comply with EMA requirements. As ANKTIVA advances toward EU market entry, the company is finalizing distribution strategies for sustainable and equitable access.
Strong Trial Data Underscores Market Potential
IBRX presented robust data from a single-arm trial involving 100 adults with BCG-unresponsive NMIBC. The combination treatment produced responses lasting an average of 27 months, with some exceeding 54 months. At 12 months, 66% of responders remained cancer-free, and at 24 months, the figure stood at 42%.
This data set supported the EMA’s decision to issue a conditional recommendation, highlighting the drug’s clinical significance. IBRX plans to follow up with trial participants to track long-term safety and efficacy outcomes. The company also emphasized that multiple BCG strains available in Europe will support broader adoption of ANKTIVA.
IBRX continues development of a recombinant BCG candidate to help mitigate U.S. supply shortages. This strategic move ensures that eligible patients maintain consistent access to ANKTIVA treatment. The company remains committed to addressing bladder cancer with innovative immune-based therapies.
Market Reacts to Breakout as IBRX Holds Near Highs
IBRX stock maintained strong momentum throughout the session, driven by the EMA announcement. The bullish breakout above $2.30 pushed the price near $2.45, holding gains into resistance. Market participants showed renewed confidence in the stock as buyers remained in control.
Price action suggests strength, though the $2.50 level could trigger profit-taking or short-term volatility. IBRX saw increased volume, signaling strong conviction behind the move. The technical setup reinforces optimism for continued upside should resistance levels break.
IBRX is now positioned to capitalize on international regulatory tailwinds. The company’s focus on immune therapies, especially ANKTIVA, supports long-term growth potential. With EMA support secured, IBRX continues to strengthen its global presence in bladder cancer treatment.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
